Chemocentryx Inc (CCXI) investors sentiment decreased to 0.93 in 2018 Q4. It’s down -0.05, from 0.98 in 2018Q3. The ratio dropped, as 42 funds started new and increased positions, while 45 sold and reduced their stakes in Chemocentryx Inc. The funds in our database now possess: 27.13 million shares, up from 26.80 million shares in 2018Q3. Also, the number of funds holding Chemocentryx Inc in top ten positions was flat from 1 to 1 for the same number . Sold All: 7 Reduced: 38 Increased: 24 New Position: 18.
The stock of Fortinet, Inc. (NASDAQ:FTNT) hit a new 52-week high and has $97.75 target or 3.00% above today’s $94.90 share price. The 9 months bullish chart indicates low risk for the $16.19 billion company. The 1-year high was reported on Apr, 15 by Barchart.com. If the $97.75 price target is reached, the company will be worth $485.79 million more. The stock increased 2.36% or $2.19 during the last trading session, reaching $94.9. About 1.25M shares traded. Fortinet, Inc. (NASDAQ:FTNT) has risen 69.30% since April 15, 2018 and is uptrending. It has outperformed by 64.93% the S&P500. Some Historical FTNT News: 04/05/2018 – FORTINET INC FTNT.O : UBS RAISES TARGET PRICE TO $64 FROM $62; 16/05/2018 – Fortinet Threat Landscape Report Reveals an Evolution of Malware to Exploit Cryptocurrencies; 03/05/2018 – Fortinet quarterly profit surges; 15/05/2018 – Fortinet Presenting at JPMorgan Conference Tomorrow; 28/03/2018 – Pulse Secure NAC Integrates with Fortinet Security Fabric to Enrich Endpoint Intelligence and Automate Threat Response; 13/04/2018 – Fortinet Presenting at RSA Conference Apr 18; 11/04/2018 – Media Advisory: Fortinet to Showcase the Third and the Latest Generation of Network Security with the Evolution of its Security Fabric at RSA Conference 2018; 11/04/2018 – Arista Networks Joins Fortinet Fabric-Ready Partner Program to Advance Security Automation Across Data Center and Cloud; 11/04/2018 – Arista Networks Joins Fortinet Fabric-Ready Partner Program to Advance Security Automation Across Data Center and Cloud Networks; 17/04/2018 – Fortinet Now Part of IBM Security’s New X-Force Threat Management Services
More notable recent Fortinet, Inc. (NASDAQ:FTNT) news were published by: Nasdaq.com which released: “Fortinet (FTNT) Stock Moves 0.12%: What You Should Know – Nasdaq” on April 11, 2019, also Nasdaq.com with their article: “First Week of FTNT May 17th Options Trading – Nasdaq” published on March 21, 2019, Nasdaq.com published: “Noteworthy Thursday Option Activity: FTNT, WMT, SIX – Nasdaq” on April 11, 2019. More interesting news about Fortinet, Inc. (NASDAQ:FTNT) were released by: Nasdaq.com and their article: “Fortinet Unveils Industry’s First SD-WAN ASIC to Accelerate and Secure the WAN Edge – Nasdaq” published on April 09, 2019 as well as Nasdaq.com‘s news article titled: “Fortinet (FTNT) Outpaces Stock Market Gains: What You Should Know – Nasdaq” with publication date: April 01, 2019.
Analysts await Fortinet, Inc. (NASDAQ:FTNT) to report earnings on May, 2. They expect $0.20 EPS, up 17.65% or $0.03 from last year’s $0.17 per share. FTNT’s profit will be $34.13 million for 118.63 P/E if the $0.20 EPS becomes a reality. After $0.42 actual EPS reported by Fortinet, Inc. for the previous quarter, Wall Street now forecasts -52.38% negative EPS growth.
Fortinet, Inc. provides cybersecurity solutions for enterprises, service providers, and government organizations worldwide. The company has market cap of $16.19 billion. The firm offers FortiGate physical and software licenses that provide various security and networking functions, including firewall, intrusion prevention, anti-malware, virtual private network, application control, Web filtering, anti-spam, and wide area network acceleration; FortiManager product family to provide a central management solution for FortiGate products comprising software updates, configuration, policy settings, and security updates; and the FortiAnalyzer product family, which offers a single point of network log data collection. It has a 49.69 P/E ratio. It also provides FortiAP secure wireless access points; FortiWeb, a Web application firewall; FortiMail email security; FortiDB database security appliances; FortiClient, an endpoint security software; and FortiSwitch secure switch connectivity products.
Among 9 analysts covering Fortinet (NASDAQ:FTNT), 3 have Buy rating, 1 Sell and 5 Hold. Therefore 33% are positive. Fortinet had 12 analyst reports since October 19, 2018 according to SRatingsIntel. The stock has “Sell” rating by Goldman Sachs on Friday, January 4. The firm earned “Neutral” rating on Friday, November 2 by Citigroup. The stock of Fortinet, Inc. (NASDAQ:FTNT) earned “Neutral” rating by JP Morgan on Friday, November 2. Mizuho initiated the shares of FTNT in report on Tuesday, March 26 with “Hold” rating. The firm earned “Market Perform” rating on Tuesday, January 22 by BMO Capital Markets. On Tuesday, November 20 the stock rating was upgraded by Raymond James to “Outperform”. BMO Capital Markets maintained Fortinet, Inc. (NASDAQ:FTNT) rating on Friday, November 2. BMO Capital Markets has “Outperform” rating and $90 target. The company was upgraded on Friday, February 8 by First Analysis.
Since January 1, 0001, it had 0 insider buys, and 7 sales for $1.80 million activity.
The stock decreased 2.36% or $0.31 during the last trading session, reaching $12.82. About 89,823 shares traded. ChemoCentryx, Inc. (CCXI) has risen 12.22% since April 15, 2018 and is uptrending. It has outperformed by 7.85% the S&P500. Some Historical CCXI News: 23/05/2018 – ChemoCentryx Announces Two Upcoming Presentations at the 55th ERA-EDTA Congress; 09/03/2018 – ChemoCentryx Expects to Utilize Between $65M-$75M Cash and Investments in FY18; 09/05/2018 – CHEMOCENTRYX INC – EXPECTS TO UTILIZE CASH AND INVESTMENTS BETWEEN $65 MLN AND $75 MLN FOR TWELVE MONTHS ENDING DECEMBER 31, 2018; 09/03/2018 ChemoCentryx 4Q EPS 80c; 09/03/2018 – CCXI TO BEGIN AVACOPAN CLINICAL STUDIES IN HS BY ’18 END; 09/03/2018 – CCXI PLANS TO START DEVT AVACOPAN IN HIDRADENITIS SUPPURATIVA; 20/04/2018 – DJ Chemocentryx Inc, Inst Holders, 1Q 2018 (CCXI); 09/03/2018 – ChemoCentryx Intends to Initiate Clinical Development of Avacopan in Hidradenitis Suppurativa by Yr-En; 22/03/2018 – ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in the Treatment of Focal Segmental Glomerulosclerosis (FSGS); 09/05/2018 – CHEMOCENTRYX INC – QTRLY DILUTED NET LOSS PER COMMON SHARE $0.19
More notable recent ChemoCentryx, Inc. (NASDAQ:CCXI) news were published by: Globenewswire.com which released: “ChemoCentryx Appoints Rita Jain, M.D. to Board of Directors – GlobeNewswire” on March 28, 2019, also Benzinga.com with their article: “52 Biggest Movers From Yesterday – Benzinga” published on March 26, 2019, Benzinga.com published: “60 Stocks Moving In Wednesday’s Mid-Day Session – Benzinga” on March 27, 2019. More interesting news about ChemoCentryx, Inc. (NASDAQ:CCXI) were released by: Benzinga.com and their article: “10 Biggest Price Target Changes For Wednesday – Benzinga” published on March 27, 2019 as well as Benzinga.com‘s news article titled: “Cancer Biology Clinical Research Seeking Answers at Cellular Level – Benzinga” with publication date: March 26, 2019.
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. The company has market cap of $740.05 million. The Company’s lead drug candidate is Avacopan , an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor (C5Ar), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). It currently has negative earnings. The firm also engages in developing CCX140, an inhibitor of the chemokine receptor known as CCR2 for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease; Vercirnon for the treatment of patients with moderate-to-severe CrohnÂ’s diseases; CCX872, a selective inhibitor of the human CCR2 that has completed Phase I clinical trial for the treatment of pancreatic cancer; CCX507, which has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and Th17 cells for the treatment of psoriasis, rheumatoid arthritis, asthma, and multiple sclerosis.
Bvf Inc Il holds 9.54% of its portfolio in ChemoCentryx, Inc. for 6.69 million shares. P.A.W. Capital Corp owns 50,000 shares or 0.68% of their US portfolio. Moreover, Sio Capital Management Llc has 0.67% invested in the company for 169,257 shares. The Utah-based Wasatch Advisors Inc has invested 0.34% in the stock. Nantahala Capital Management Llc, a Connecticut-based fund reported 623,338 shares.